Rheumatology Medical News about Malignanacy, SLE, Lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Malignancy in systemic lupus erythematosus: What have we learned?
Best Practice & Research: Clinical Rheumatology, 07/28/09

Bernatsky S et al. – This article summarizes what we have learned to date regarding the links between systemic lupus erythematosus (SLE) and malignancy.

There is evidence that immune system activity plays a role in the development of some lymphomas
However, there is also evidence that immunosuppressive medications can influence the development of certain cancers, and pre-cancerous states such as cervical dysplasia
There is evidence of increased risk related to some medication for cervical dysplasia particularly to cyclophosphamide
Important questions still remain regarding the independent influences of medication exposures vs disease activity on lymphoma risk in SLE
Establishing which molecular pathways mediate the association between lymphoma and SLE will also be of great value
A related research priority is the development of effective SLE treatments that could take the place of toxic agents such as cyclophosphamide

<< Previous
Paget's disease of bone—becoming a rarity?

Next >>
Shoulder arthritis and the young patient